For example, there is a subset of cutaneous melanomas with activating mutations in serine/threonine protein kinase B-Raf (BRAF) or GTPase N-Ras (NRAS), another subset with high tumor mutation burden and sensitivity to checkpoint inhibitors, or another with neither BRAF or NRAS mutations and low tumor mutation burden. This evidence concerns the gene BRAF and melanoma.